In recent decades, there has been a significant increase in the incidence and prevalence of diabetes mellitus. Diabetes mellitus is characterized by the development of vascular complications leading to early disability and a decrease in the life expectancy of patients. Aging of the body inevitably leads to the occurrence of age-related diseases, including the cardiovascular system, and increases the risk of death. Metabolic and structural and functional disorders of the cardiovascular system arising in diabetes mellitus have common pathophysiological mechanisms with aging of the body. Chronic hyperglycemia can accelerate the aging process and play a decisive role in the occurrence and prognosis of cardiovascular events in patients with diabetes mellitus. Achieving target glycemic values is an important step towards preventing vascular complications in patients with diabetes mellitus. Improved models of glucometers, equipped with a number of additional functions, allow for structured self-control of glycemia, analyze the data obtained and carry out timely correction of therapy, actively involve patients in the process of diabetes management, which will significantly increase the efficiency of disease management, reduce the risk of complications in patients and improve the quality of life.

Currently glycaemia is proved to be an independent risk factor of cardiovascular events in diabetes mellitus patients. The article considers potential hypoglycaemia action mechanisms on the cardiovascular system and glycaemia self-control issues in diabetes mellitus.

It is now well established that clinical use of statins for primary and secondary prevention of cardiovascular complications in patients with diabetes mellitus (DM) increases life expectancy. At the same time, meta-analysis of major randomized trials shows statins to increase glycemic levels and incidence of diabetic symptoms, especially in patients at risk for developing glycemic disorders. However, comparison of positive and negative effects of statins suggests prevalence of clinically beneficial factors.

It is now well established that clinical use of statins for primary and secondary prevention of cardiovascular complications in patientswith diabetes mellitus (DM) increases life expectancy. At the same time, meta-analysis of major randomized trials shows statins to increaseglycemic levels and incidence of diabetic symptoms, especially in patients at risk for developing glycemic disorders. However,comparison of positive and negative effects of statins suggests prevalence of clinically beneficial factors.

It is known that hypoglycemia is associated with an increased risk of cardiovascular adverse events including death. ACE-inhibitors, when taken with antidiabetic drugs, can cause hypoglycemic episodes by improving insulin sensitivity. This clinical case illustrates the necessity to monitor plasma glucose in the early phase of the treatment by the ACE-inhibitors in diabetic patients.

Congestive heart failure, diabetes mellitus, and ciliary arrhythmia are three epidemic cardiovascular conditions threatening the mankind in the XXI century. Ciliary arrhythmia is the commonest disturbance of cardiac rhythm characterized by inability of the atrium to maintain coordinated contractions. The importance of ciliary rrhythmia as a problem facing public heath services is underlain by its role as a risk factor of disturbed cerebral circulation and severe cardiac insufficiency, the two most serious and costly cardiovascular complications influencing life expectancy of the affected subjects.

The modern algorithm of hypoglycemic therapy for patients with type 2 diabetes mellitus (DM2) has been designed to effectively reach the "target" blood glucose and HbA1c levels associated with the lowest mortality rate. The most popular scheme is combined treatment with metformin andsulfonylureas thatmakes possible the achievement of the "target" metabolic indices in the majority of DM2 patients. However, specific cardiovascular efficiency of this therapy is a matter of controversy. The safest modalities of combined therapy are discussed based on the analysis of relevant epidemiological data.

В Праге13-16 мая 2010 г. в третий раз состоялся конгресс ?От противоречий к консенсусу в диабете, ожирении и гипертонии? (World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension). В соответствии с названием, конгресс построен по принципу представления различных, подчас противоположных мнений по основным проблемам диабетологии, итогом которых являются потря- сающе интересные дискуссии.